Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer

BACKGROUND: A small proportion of patients with non-small cell lung cancer (NSCLC) experience objective clinical benefit after neoadjuvant programmed cell death 1 (PD-1) blockade. A neoadjuvant therapeutic regimen combining immune checkpoint blockade with chemotherapy might improve the treatment eff...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Transl Lung Cancer Res
Main Authors: Chen, Yulong, Yan, Bo, Xu, Feng, Hui, Zhenzhen, Zhao, Gang, Liu, Jie, Zhang, Huan, Zeng, Ziqing, Zhang, Ran, Provencio, Mariano, Ren, Xiubao, You, Jian
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2021
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8182703/
https://ncbi.nlm.nih.gov/pubmed/34164269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-329
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki